We are live on ! Find out more
EIKN

Eikon Therapeutics

7.92 USD
-0.37
4.46%
At close Updated Sep 25, 4:00 PM EDT
Pre-market
After hours
8.03
+0.11
1.39%
1 day
-4.46%
5 days
-12.58%
1 month
-36.89%
3 months
-19.59%
6 months
-28.46%
Year to date
-47.2%
1 year
-47.2%
5 years
-47.2%
10 years
-47.2%
 

About: Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.

Employees: 384

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 10%
Neutral 90%
Negative 0%
Neutral
Seeking Alpha
10 days ago
Eikon Therapeutics, Inc. (EIKN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Eikon Therapeutics, Inc. (EIKN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Eikon Therapeutics, Inc. (EIKN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Neutral
GlobeNewsWire
23 days ago
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
MILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the appointment of Ching-Pin (“CP”) Chang, M.D.
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
Neutral
GlobeNewsWire
1 month ago
Eikon Therapeutics to Participate in Investor Conferences in September 2026
MILLBRAE, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that Roger M. Perlmutter, M.D., Ph.D., Chairman and Chief Executive Officer, and Freddie Bowie, Ph.D., Chief Financial Officer, will participate in two upcoming investor conferences taking place in September:
Eikon Therapeutics to Participate in Investor Conferences in September 2026
Positive
MarketBeat
1 month ago
Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004
Eikon Therapeutics NASDAQ: EIKN outlined its development strategy for selective PARP1 inhibitors and its Werner helicase inhibitor during a discussion hosted by Cantor biotech analyst Imogen Mansfield. President, Chief Executive Officer and Board Chair Roger Perlmutter and MD Anderson Cancer Center's Vice President and Head of Clinical Development Tim Yap discussed the rationale for improving on earlier PARP inhibitor therapies, which commonly inhibit both PARP1 and PARP2.
Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004
Neutral
Seeking Alpha
1 month ago
Eikon Therapeutics, Inc. (EIKN) Discusses Advances in PARP1 Biology and Next-Generation PARP Inhibitors in Oncology Transcript
Eikon Therapeutics, Inc. (EIKN) Discusses Advances in PARP1 Biology and Next-Generation PARP Inhibitors in Oncology Transcript
Eikon Therapeutics, Inc. (EIKN) Discusses Advances in PARP1 Biology and Next-Generation PARP Inhibitors in Oncology Transcript
Neutral
GlobeNewsWire
1 month ago
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
Chairman and Chief Executive Officer, Roger M. Perlmutter, M.D., Ph.D., will participate in a key opinion leader (KOL) event on Thursday, August 20, 2026
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
Neutral
GlobeNewsWire
1 month ago
Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
MILLBRAE, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today reported second quarter 2026 financial results and provided updates on its programs.
Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
Neutral
GlobeNewsWire
1 month ago
Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board
MILLBRAE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the addition of Johnny Bennett, Ph.D.
Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board
Neutral
GlobeNewsWire
2 months ago
Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer
MILLBRAE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that the first patient has been dosed in TeLuRide-008, a Phase 2/3 registrational study evaluating EIK1001 in combination with pembrolizumab and histology-appropriate chemotherapy as first-line therapy for treatment-naïve patients with stage 4 Non-Small Cell Lung Cancer (NSCLC).
Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer
Neutral
GlobeNewsWire
2 months ago
Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress
Presentations to cover updates across Eikon's clinical pipeline including:  Updated data from TeLuRide-005, an ongoing Phase 2 trial of EIK1001, a TLR7/8 dual agonist, plus pembrolizumab and chemotherapy in stage 4 non-small cell lung cancer (NSCLC) Updated cohort data from an ongoing Phase 1/2 study of EIK1003, a highly selective non-brain penetrant PARP1 inhibitor, as monotherapy and in combination with chemotherapy in advanced solid tumors Initial data from a Phase 1/2 study of EIK1003 in combination with the novel hormonal agent abiraterone in metastatic prostate cancer Initial results from an ongoing Phase 1/2 study of EIK1004, a highly selective CNS-penetrant PARP1 inhibitor in advanced solid malignancies Initial safety, tolerability and pharmacokinetics data for EIK1005, a Werner (WRN) helicase inhibitor MILLBRAE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the acceptance of seven abstracts covering progress across its lead programs at the 2026 European Society of Medical Oncology (ESMO) Congress in Madrid, Spain.
Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress
Price charts implemented using Lightweight Charts™